AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04354662
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2600 mg/m², d1
Trial: NCT04354662
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m², d1
Trial: NCT00249912
Drug: Lapaquistat acetate and rosuvastatin
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Trial: NCT00249912
Drug: Lapaquistat acetate and rosuvastatin
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Trial: NCT00249912
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
Trial: NCT02396706
Drug: Ivy Leaves Cough Liquid
RxNorm normalized name: digitalis leaves
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02396706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02425969
Drug: Optimal Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
Trial: NCT00828230
Drug: Placebo foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One application of placebo foam once daily for 8 weeks
Trial: NCT04577378
Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
Trial: NCT04577378
Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
Trial: NCT01749878
Drug: REGN1500
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01749878
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03896321
Drug: Antiplatelet Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effect of dual antiplatelet in management of coronary artery ectasia
Trial: NCT03896321
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effect of oral anticoagulants in management of coronary artery ectasia
Trial: NCT00879047
Drug: Alcohol placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
Trial: NCT02208505
Drug: Dexmedetomidine + Remifentanil-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
Trial: NCT02208505
Drug: Remifentanil-high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
Trial: NCT03121963
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen tablet
Trial: NCT03121963
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib tablet
Trial: NCT00095004
Drug: Comparator: placebo / Duration of Treatment: 1 day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00639015
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
Trial: NCT01367561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02165605
Drug: HylaCare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream
Trial: NCT02165605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04655118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match TL-895
Trial: NCT03068468
Drug: BIIB092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB092 intravenous infusion on specified days
Trial: NCT01035671
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 days of placebo oral capsules. Treatment taken twice daily with meals.
Trial: NCT03068468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion on specified days
Trial: NCT02217683
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
Trial: NCT00799903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in addition to standard therapy
Trial: NCT01926002
Drug: High-Dose MK-8351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose MK-8351 administered as a single inhaled dose.
Trial: NCT01926002
Drug: Placebo to MK-8351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Dose Matching placebo to high-dose or low-dose MK-8351.
Trial: NCT03126084
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of intravenous acetaminophen will be administered twice a day
Trial: NCT00328523
Drug: Duration of Treatment: 3 months
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02067936
Drug: Group A propofol + remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predicted TOL90% according to Bouillon model
Trial: NCT02067936
Drug: Group B propofol + remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOL 90% according to the Bouillon interaction model
Trial: NCT02067936
Drug: Group C propofol + remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOL 90% according to the Bouillon interaction model
Trial: NCT02067936
Drug: group D propofol + remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOL 90% according to the Bouillon interaction model
Trial: NCT01510912
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 35 mg bid or tid Capsules
Trial: NCT05307614
Drug: Moksi® 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
Trial: NCT05307614
Drug: Drug: Avelox® 400Mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
Trial: NCT00202358
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00652301
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
Trial: NCT03710642
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matched to appearance of active drug.
Trial: NCT00034294
Drug: GT160-246
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03030118
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
Trial: NCT01648972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02219672
Drug: Triplitode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir .
Trial: NCT01090024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 671800
Trial: NCT04328441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneously 0.1ml NaCl 0,9%
Trial: NCT03733132
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment of identical tablets to metformin group
Trial: NCT04385186
Drug: Support treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
Trial: NCT00149630
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
Trial: NCT01587040
Drug: SAR245408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule or tablet Route of administration: oral
Trial: NCT01587040
Drug: SAR245409
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule or tablet Route of administration: oral
Trial: NCT01564563
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of bleeding
Trial: NCT02857491
Drug: sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham intravitreal injection before vitrectomy
Trial: NCT01365403
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
Trial: NCT01564563
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02184325
Drug: Kiddi® Pharmaton Fizz, effervescent tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02184325
Drug: Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02184325
Drug: Comparator product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
Trial: NCT00611767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
Trial: NCT03862833
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg at day +15 post graft
Trial: NCT00801216
Drug: High-dose sequential chemotherapy and autologous transplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
Trial: NCT00141622
Drug: Slow sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00722215
Drug: 0.9 % saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 15ml 0.9% saline infused for 15 mins as placebo control
Trial: NCT03400475
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One topical application in peri-implant gingival crevice
Trial: NCT00108771
Drug: ZR-02-01 Fentanyl Transdermal Matrix Patch
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
Trial: NCT00108771
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
Trial: NCT01072357
Drug: Avastin® (bevacizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
Trial: NCT02390258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00809055
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine to be administered as outlined to compare efficacy of different dosages.
Trial: NCT04246541
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.
Trial: NCT04246541
Drug: Oxycodone-Acetaminophen
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
Trial: NCT01493934
Drug: injection of 6-DIG
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unique injection dose of 92.5 MBq
Trial: NCT02078089
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
Trial: NCT02001506
Drug: FEC3-D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks
Trial: NCT00434187
Drug: ERB-041
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03915470
Drug: XF-73
RxNorm normalized name: Exeporfinium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
Trial: NCT01233050
Drug: 2% Chlorhexidine Gluconate/70% Isopropyl Alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative skin antisepsis preparation
Trial: NCT04168619
Drug: Discontinue methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
Trial: NCT03915470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match XF-73 nasal gel for colour and viscosity.
Trial: NCT03160898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT00078247
Drug: Tuberculosis treatment
RxNorm normalized name: Hydrazides for tuberculosis treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculosis treatment
Trial: NCT04179604
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
Trial: NCT00920686
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered as 3 placebo hard gelatin capsules
Trial: NCT04599972
Drug: CSF-1
RxNorm normalized name: CSF-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop bilaterally twice daily for approximately 2 weeks.
Trial: NCT04599972
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop bilaterally twice daily for approximately 2 weeks.
Trial: NCT03014830
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections SQ every 2 weeks
Trial: NCT01150097
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
Trial: NCT00610688
Drug: Prenatal Vitamin
RxNorm normalized name: Prenatal Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
Trial: NCT01063023
Drug: Ortho Tri-Cyclen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 1 Tablet, once daily
Trial: NCT00955396
Drug: GSK1014802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT00955396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT00992459
Drug: HPN-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
Trial: NCT01236768
Drug: AG200-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period.
Trial: NCT02717052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
Trial: NCT00939848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg od (continuous dosing) until evidence of disease progression has been confirmed
Trial: NCT04370782
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
Trial: NCT04370782
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 220mg once daily for 5 days
Trial: NCT04370782
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg once daily for 5 days
Trial: NCT01909986
Drug: [14C]ONO-4053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose \[14C\]ONO-4053
Trial: NCT00111891
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03321539
Drug: CCRT+GP
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
Trial: NCT00565708
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant Therapy